Evidence map›Paper›PMID 35132958›Full record

ArticleJCI insight2022

NK cells require immune checkpoint receptor LILRB4/gp49B to control neurotropic Zika virus infections in mice.

Ha-Na Lee, Mohanraj Manangeeswaran, Aaron P Lewkowicz, Kaliroi Engel, Monica Chowdhury, Mamatha Garige, Michael A Eckhaus, Carole Sourbier, Derek Dc Ireland, Daniela Verthelyi

Open access · goldAbstract read
In one paragraph

Article in JCI insight, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Peptide-based drugs in immunotherapy: current advances and future prospects.Medical oncology (Northwood, London, England) · 2025
    Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Innate lymphoid cells in neuroinflammation.Frontiers in cellular neuroscience · 2024
    Review
  12. Effects ofInternational journal of molecular sciences · 2023
    Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Ha-Na LeeLaboratory of Immunology, Center of Excellence in Infectious Disease and Inflammation, Office of Biotechnology Products, and.
Mohanraj ManangeeswaranLaboratory of Immunology, Center of Excellence in Infectious Disease and Inflammation, Office of Biotechnology Products, and.
Aaron P LewkowiczLaboratory of Immunology, Center of Excellence in Infectious Disease and Inflammation, Office of Biotechnology Products, and.
Kaliroi EngelLaboratory of Immunology, Center of Excellence in Infectious Disease and Inflammation, Office of Biotechnology Products, and.
Monica ChowdhuryLaboratory of Immunology, Center of Excellence in Infectious Disease and Inflammation, Office of Biotechnology Products, and.
Mamatha GarigeLaboratory of Molecular Oncology, Division of Biotechnology Review and Research-I, Office of Biotechnology Products, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research (CDER), US Food and Drug Administration (FDA), Silver Spring, Maryland, USA.
Michael A EckhausDivision of Veterinary Resources, Office of Research Services, National Institutes of Health (NIH), Bethesda, Maryland, USA.
Carole SourbierLaboratory of Molecular Oncology, Division of Biotechnology Review and Research-I, Office of Biotechnology Products, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research (CDER), US Food and Drug Administration (FDA), Silver Spring, Maryland, USA.
Derek Dc IrelandLaboratory of Immunology, Center of Excellence in Infectious Disease and Inflammation, Office of Biotechnology Products, and.
Daniela VerthelyiLaboratory of Immunology, Center of Excellence in Infectious Disease and Inflammation, Office of Biotechnology Products, and.
Center for Drug Evaluation and Research · USOffice of Research Services · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune cells express an array of inhibitory checkpoint receptors that are upregulated upon activation and limit tissue damage associated with excessive response to pathogens or allergens. Mouse leukocyte immunoglobulin like receptor B4 (LILRB4), also known as glycoprotein 49B (gp49B), is an inhibitory checkpoint receptor constitutively expressed in myeloid cells and upregulated in B cells, T cells, and NK cells upon activation. Here, we report that expression of LILRB4, which binds Zika virus (ZIKV), was increased in microglia and myeloid cells infiltrating the brains of neonatal mice with ZIKV-associated meningoencephalitis. Importantly, while C57BL/6 mice developed transient neurological symptoms but survived infection, mice lacking LILRB4/gp49B (LILRB4 KO) exhibited more severe signs of neurological disease and succumbed to disease. Their brains showed increased cellular infiltration but reduced control of viral burden. The reduced viral clearance was associated with altered NK cell function in the absence of LILRB4/gp49B. In naive animals, this manifested as reduced granzyme B responses to stimulation, but in ZIKV-infected animals, NK cells showed phenotypic changes that suggested altered maturation, diminished glucose consumption, reduced IFN-γ and granzyme B production, and impaired cytotoxicity. Together, our data reveal LILRB4/gp49B as an important regulator of NK cell function during viral infections.

Indexed as

Gene Expression RegulationZika VirusAnimalsB-LymphocytesDisease Models, AnimalFemaleKiller Cells, NaturalMaleMembrane GlycoproteinsMiceMice, Inbred C57BLMice, TransgenicReceptors, ImmunologicRNAT-LymphocytesZika Virus InfectionLilrb4 protein, mouseMembrane GlycoproteinsReceptors, ImmunologicRNAImmunologyInfectious diseaseNK cells

Identifiers

PMID35132958
PMCPMC8855830
OpenAlexW4210559116

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.